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New insights into proteasome function: from 
archaebacteria to drug development 
The proteasome is not simply a ‘garbage disposal unit’ but also has functions in the 
control of the cell cycle and immune responses. The structure of an archaebacterial 
proteasome has recently been determined to high resolution, and provides insight into 
the unusual mechanism of proteolytic cleavage by the proteasome. 
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Since the introduction of isotopic tracers into biochem- many as 22 different names in the literature; many func- 
istry over 50 years ago, it has been known that intracellu- tions were proposed for it that were unrelated to protein 
lar proteins, once synthesized, are continually being turnover [4]. It was eventually named the ‘proteasome’ to 
degraded back to their constituent amino acids. But clear indicate a particle with proteolytic function [4]. Since 
ideas about the degradative pathways responsible, the then, antibody studies in vitro, reconstitution, and finally 
proteolytic machinery involved, the mode of action of mutant studies in yeast have shown that the 20s particle 
the enzymes required, and the physiological significance functions in the ubiquitin-dependent pathway as the pro- 
of the process have only recently emerged. It is now teolytic core of the 26s complex [9,10]. Formation of this 
known that the bulk of cell proteins are hydrolyzed by a larger structure involves an ATP-dependent association of 
soluble ATP-dependent system that is present in both the the 20s proteasome with a 19s (600 kDa) particle 
nucleus and cytosol [l]. Protein substrates are first [ 11,121, which appears to function as the ‘mouth’ for the 
marked for degradation by covalent conjugation to mul- 20s particle (Fig. 2); it binds substrates, probably unfolds 
tiple molecules of a small protein, ubiquitin [l]. This them, and injects the polypeptides into the 20s protea- 
process involves the activation of ubiquitin by the forma- some for digestion [2,8]. The 19s particle contains five 
tion of a thiol-ester at its carboxyl terminus, which is distinct ATPases, a binding site for ubiquitin chains [13], 
then transferred to the E-amino group on a lysine residue and at least one isopeptidase [14], which disassembles the 
on the protein (Fig. 1). Other ubiquitin molecules are ubiquitin chain during protein hydrolysis. Despite this 
processively linked to the first, forming long chains of exciting recent progress, many aspects of the function of 
ubiquitin on the substrate.This triggers the rapid hydrol- the 26s proteasome complex remain mysterious. For 
ysis of the substrate by a very large ATP-dependent pro- example, the function of ATP hydrolysis is not known. We 
teolytic complex, termed the 26s proteasome (for useful 
reviews, see [2-81). The proteolytic core of this 2000 kDa 
do not understand why degradation of some polypeptides 
(e.g. the enzyme ornithine decarboxylase) does not 
(26-30s) structure is the 20s proteasome, a 700-kDa require ubiquitination [15], nor do we know whether the 
particle containing multiple peptidase activities [2-8). 20s particle ever breaks down proteins by itself in vim. 
The 20s proteasome is a major cellular constituent; it 
comprises -1 % of the protein in most cells. It was discov- 
ered independently by several labs, and had received as 
Structure of the 20s particle 
The mammalian 700 kDa proteasome is a barrel-shaped 
particle composed of four stacked oligomeric rings, two 
Fig. 1. The ubiquitin-proteasome 
pathway for protein degradation. 
Ubiquitin is first activated by an enzyme 
complex (El-E3), which generates a 
thiol-ester at the carboxyl-terminus of 
the protein. This is then used to form an 
isopeptide bond to the e-amino group 
on a lysine residue on the substrate. 
Other ubiquitin molecules are proces- 
sively linked to the first, forming long 
chains of ubiquitin on the substrate. This 
leads to rapid, ATP-dependent hydrolysis 
of the substrate by the 26s proteasome. 
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outer (a) rings and two inner (p) rings . Each ring con- 
tains seven distinct 20-30 kDa subunits [5-71. The struc- 
ture was first revealed by electron microscopic studies; 
more recently, electron microscopic tomography [ 16,171 
and X-ray diffraction analyses [18] have provided a more 
detailed structure. These important advances have been 
made possible by studies of the proteasome from the 
archaebacterium Thermoplasma acidophilum, which contains 
only two types of subunit, (Y and p, arranged in four rings 
of seven ((Y~&&x,) [ 16,181 .The eukaryotic proteasome 
has a very similar quaternary structure [5-7,161 even 
though it contains seven different, but related, a-subunits 
and seven different, but related P-subunits, which are 
encoded by distinct genes [19] (see below). The 
7’hermoplasma proteasome thus offers the advantage of 
increased symmetry, and is also more stable. The detailed 
structure of the archaebacterial proteasome has provided 
insight into issues such as the mechanism of proteolysis 
and the site at which proteolytic cleavage occurs. 
The tertiary structures of the (Y- and P-subunits are 
remarkably similar [18]. Each subunit is a sandwich of 
five-stranded anti-parallel P-sheets, flanked by a-helices 
on the top and bottom.There is tight contact between 
the (Y- and P-subunits in adjacent rings, and together 
they help define three distinct chambers within the pro- 
teasome, which are connected by a central pore (Fig. 3). 
The minor outer chambers are defined by the space 
between the (Y- and P-rings, and a larger central 
chamber is defined by the inner walls of the P-subunits. 
Lowe et al. [18] analyzed proteasome crystals containing 
a peptide aldehyde inhibitor, and found that each of the 
14 P-subunits contains a site for inhibitor binding, which 
presumably corresponds to the enzyme’s active site.The 
active sites are positioned in the central chamber. 
Intracellular proteolysis must be an extremely selective 
process for the integrity of the cell to be maintained. 
One would therefore assume that structural safeguards 
might have evolved to prevent nonspecific digestion of 
cell constituents.The isolation of the proteasome’s active 
sites within the central chamber of the particle probably 
helps to reduce unselective proteolysis. Polypeptide entry 
into the 20s Thermoplasma proteasome requires that the 
substrate be unfolded [17]. The recent X-ray diffraction 
studies [18] confirmed the existence of a small central 
Fig. 2. Relationship between the 20s 
proteasome (left) and 26s proteasome 
(right). The 2OS proteasome is composed 
of two central P-subunit rings, with two 
outer a-subunit rings, each with seven 
members. Addition of the 19s regulatory 
complex to the top and bottom of the 
20s proteasome forms the 26s protea- 
some. The 195 particle contains a bind- 
ing site for ubiquitin chains and several 
ATPase activities. The 26s proteasome is 
responsible for the degradation of ubiq- 
uitin-protein conjugates; degradation is 
ATP-dependent. 
pore in the a-rings, 13 A in diameter, through which a 
polypeptide must pass to enter the central cavity. 
Presumably, this entry point is also a site of regulation, 
and factors that activate peptide hydrolysis by the 20s 
particle (e.g. the 19s complex [12]) may do so by enlarg- 
ing this opening and facilitating substrate entry. In the 
26s complex, chemical free energy derived from ATP 
hydrolysis may be transduced into mechanical energy 
and used to catalyze unwinding of the polypeptide sub- 
strate and injection of the polypeptide into the prote- 
olytic core. The requirement for ubiquitination of 
substrates for degradation in eukaryotes [1,4] probably 
evolved to ensure that polypeptide entry into this 20s 
proteasome is highly selective. 
It has previously been noted that protein degradation by 
the proteasome generally results in oligopeptides of 
about 6-10 amino acids [20]. There is some reason to 
believe that the size of these peptides is important, par- 
ticularly for the function of the proteasome in antigen 
presentation. Lowe ef al. [ 181 hypothesized that polypep- 
tides undergoing degradation are attached to the wall of 
the central chamber in an extended conformation, and 
thus are susceptible to cleavage by these symmetrically 
distributed active sites. The distance between the active 
sites appears to be approximately the length of a 7-8 
amino acid peptide, when extended. 
0 Chemistry & Biology, 199: 
Fig. 3. Arrangement of the chambers within the proteasome. The space 
between the a-subunit and p-subunit rings defines the small outer 
chambers, while the space between the two p-subunit rings defines 
the large central chamber. Proteolysis takes place within the large cen- 
tral chamber; white dots indicate peptidase active sites. The target pro- 
tein must enter the chamber through a small pore in the center of the 
a-subunit ring. The 19s complex may enlarge this opening, and may 
also unfold the protein to allow it to enter the pore more easily. 
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A novel proteolytic mechanism 
The mechanism of peptide bond hydrolysis by the 20s 
proteasome has long been a puzzle. The sequences of 
the CX- and P-subunits of the proteasome show no 
homology to those of other proteases, although they are 
closely related to one another and have been highly 
conserved during evolution [6,7,19,21]. Studies using 
protease inhibitors indicated that the proteasome resem- 
bled a serine protease in certain properties, but not in 
others [5]. But mutagenesis in Thermoplasma indicated 
that no serine or cysteine residue was essential for activ- 
ity [21].The recent information on the structure of the 
particle, together with mutagenesis studies, have revealed 
that the proteasome uses a new type of catalytic mecha- 
nism. In the crystal structure, the hydroxyl group of the 
amino-terminal threonine of the P-subunit is close to 
the aldehyde carboxyl of the inhibitor Ac-Leu-Leu- 
Norleunal, and probably forms a hemiacyl intermediate 
with it.Thus, this threonine appears to function like the 
active site serine in the catalytic triad of serine pro- 
teases. Seemuller et al. [21] also showed that mutagenesis 
of this threonine to alanine prevented peptidase activity, 
while replacement with a serine did not.The terminal 
threonine residue has been highly conserved during 
evolution from archaebacteria to man. It is so far 
unclear why threonine is used as the catalytic residue 
instead of serine. 
For peptide bond hydrolysis, there must be a basic group 
to accept a proton from the active site threonine 
hydroxyl in the catalytic transition state. One likely can- 
didate is the a-amino group of the same threonine. 
Similarly, it has recently been suggested that the o-amino 
group of the catalytic serine residue in a penicillin 
acylase acts as a base during catalysis [22]. In both cases a 
lysine residue is also found near the active site, and this is 
an alternative candidate for the catalytic base [l&21]. 
The proteasome clearly lacks the traditional catalytic 
triad characteristic of serine or cysteine proteases, 
however. The lack of a reactive site histidine may explain 
why proteasomes are not covalently modified by the 
classic chloromethyl-ketone inhibitors. 
Additional chemical evidence supporting this mechanism 
and its generality has come from the unexpected discov- 
ery by Schreiber and coworkers [23] of a natural product 
inhibitor of proteasome activity, the antibiotic lactacystin. 
This agent covalently reacts with the terminal threonine 
residue on a specific P-subunit of the mammalian pro- 
teasome. Another inhibitor of the proteasome, dichloro- 
isocoumarin, also modifies this threonine residue (T. 
Akopian and A. L. G., unpublished data). Thus, the cat- 
alytic mechanism of the eukaryotic proteasome appears 
to be similar to that of the archaebacterial proteasome. 
Mammalian proteasomes have least five distinct pepti- 
dase activities, as defined by their preferences for differ- 
ent types of residues preceding the scissile bond and 
their sensitivities to different inhibitors, and therefore 
can cleave a wide variety of peptide bonds. The most 
extensively studied of these are the chymotrypsin-like 
activity (which prefers to cleave on the carboxyl side of 
aromatic residues), the tryptic-like activity (which 
prefers to cleave after basic residues), and the peptidyl- 
glutamyl activity (which cleaves after acidic residues). In 
addition, proteasomes exhibit activities that cleave pref- 
erentially after branched-chain amino acids or after 
small neutral residues. It appears very likely that most of 
these five different activities are associated with the dif- 
ferent P-subunits that are present in eukaryotic protea- 
somes. However, terminal threonine residues appear to 
be present on only four of the seven P-subunits in 
eukaryotic proteasomes [21]. Therefore, the three 
remaining P-subunits, though clearly important for pro- 
teasome structure, do not appear to contain catalytic 
sites for protein breakdown. The specific subunits 
responsible for each peptidase activity remain unclear, 
but should be resolved by systematic mutagenesis of 
these catalytic threonine residues. 
Physiological functions of the proteasome 
The ubiquitin-proteasome pathway has long been 
known to be important in degradation of damaged or 
mutated cellular proteins [4], but this is not its only 
function. Recent work [l] has shown that it is also 
essential for the degradation of various regulatory pro- 
teins. Rapid removal of these proteins is necessary for 
the control of cell growth and metabolism. For example, 
the orderly progression of cells through the mitotic or 
meiotic cycle requires the programmed ubiquitination 
and destruction of the various cyclins [24,25]. In many 
cases, ubiquitin-mediated degradation of regulatory pro- 
teins is signalled by their phosphorylation (e.g. the 
mitotic cyclin Cln 3 [25], or IKB~ (see below)). The 
proteasome is also responsible for the slow turnover of 
the bulk of cell proteins, which is also precisely regu- 
lated in many cells. For example, in starvation or disease 
states (e.g. infections, cancer or cachexia), mammals 
mobilize essential amino acids from muscle proteins by a 
hormone-induced activation of the ubiquitin-protea- 
some pathway [26-281. Under these conditions, the 
overall rate of proteolysis exceeds rates of synthesis, and 
muscle atrophy results. 
This continual turnover of cellular proteins by the 
ubiquitin-proteasome pathway is also used by the 
immune system to screen for the presence of abnormal 
intracellular proteins (for review see [29]). In this 
process, lymphocytes continually monitor small frag- 
ments of cell protein that are presented on class I major 
histocompatibility complex (MHC) molecules. Protea- 
somes initially degrade proteins to small peptides, most 
of which are rapidly hydrolyzed to amino acids by 
cytosolic exopeptidases. But some of these peptides are 
transported into the endoplasmic reticulum where they 
bind to MHC molecules and are then transported to 
the cell surface [29,30] in a process known as antigen 
presentation. If the peptides are abnormal (for example, 
if they are derived from viral proteins), they elicit cell 
destruction by cytotoxic T cells. Inhibitors that prevent 
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proteasome function have been shown to block the 
generation ofmost of the peptides presented on MHC 
class I molecules [30]. 
One of the most interesting findings in this area has 
been the discovery that, in certain pathological states, 
cytokines induce structural alterations in the protea- 
some that enhance the efficiency of antigen presenta- 
tion [31-331. For example, interferon-y induces the 
expression of two small MHC-encoded proteins, LMP2 
and LMP7 [31-351. These proteins are alternative B- 
subunits of the proteasome; in response to interferon 
they are expressed and incorporated into proteasomes 
in place of two of the the normal B-subunits [34,35]. 
The overall activity of the proteasome is thus subtly 
altered, so that these particles (‘immunoproteasomes’) 
cleave more rapidly after hydrophobic and basic 
residues, and less rapidly after acidic residues [31-341. 
The overall rate of protein breakdown is unchanged, 
but the number of peptides produced with hydropho- 
bic or basic carboxyl termini is increased. Such peptides 
are more likely to be transported into the endoplasmic 
reticulum [36], where they have access to class I MHC, 
and bind better to the peptide groove in class I MHC. 
It has recently been shown that mouse mutants lacking 
the LMP 2 [38]or LMP 7 [37] genes have a reduced 
capacity to present viral antigens. 
Our knowledge about the physiological importance of 
the ubiquitin-proteasome pathway has been limited by 
the lack of selective reagents that can inhibit its func- 
tion in viva. Recently, several such compounds have 
been identified, and have already proven very useful 
[23,30,39,40]. For example, several peptide aldehyde 
inhibitors of the proteasome reversibly block the degra- 
dation of abnormal polypeptides, short-lived normal 
proteins, and also the bulk of long-lived cell proteins 
[30]. Aside from their value as investigative tools, such 
inhibitors may have therapeutic applications; one area 
of particular interest is the possibility that they may 
suppress the inflammatory response. 
The ubiquitin-proteasome pathway in the onset of the 
inflammatory response 
The ubiquitin-proteasome pathway has recently been 
shown to regulate the activation of the transcriptional 
factor, NF-KB, which is critical in both acute and 
chronic inflammatory responses. NF-KB is a heterodimer 
composed of p50 and p65 subunits, both of which are 
members of the rel family of transcription factors 
[41,42]. NF-KB was originally discovered as an activator 
of the transcription of the immunoglobulin K light 
chain, and has since been found to be important in the 
expression of genes for several cytokines (IL-l, IL-2, 
IL-6, and TNF-o) and cell adhesion molecules 
(ICAM-1, VCAM-1, E-selectin) that are important in 
inflammatory responses. Thus, activation of NF-KB is a 
key event in a wide variety of disease states. 
There are two separate pathways for NF-KB activation 
([41,42], Fig. 4), both of which require the 
ubiquitin-proteasome pathway. In quiescent cells, the 
inhibitory protein IKBCI normally sequesters the 
p50/65 heterodimer (NF-KB) in the cytoplasm, proba- 
bly by masking its nuclear localization sequence. To 
activate the inflammatory response, IKBCX must be 
degraded. Triggers such as viral infection, free-radical 
oxygen species, or inflammatory cytokines [41] cause 
phosphorylation of IKB~ via still-unidentified signaling 
pathways. Phosphorylation of IKBU occurs at two spe- 
cific serine residues, leading to ubiquitination and rapid 
hydrolysis by the 26s proteasome complex [43]. The 
liberated p50/65 heterodimer can then translocate into 
the nucleus and bind to the promoter regions of 
NF-KB-responsive genes. 
The second, slower pathway for generation of active 
NF-KB requires limited proteolysis of the inactive NF-KB 
precursor p105/65 heterodimer, which is also sequestered 
in the cytoplasm [39]. Palombella et al. [39] showed that 
the conversion of p105 to the active p50 requires ubiqui- 
tin conjugation to ~105 and the 26s proteasome. 
The carboxy-terminal half of ~105 is then completely 
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Fig. 4. Activation of NF-KB occurs via 
two pathways, both of which require the 
proteasome. NF-KB (p65/p50) is gener- 
ally held in the cytoplasm of quiescent 
cells either in complex with the inhibi- 
tory factor, IKBCI, or as the precursor 
complex (plO5/p65). A variety of inflam- 
matory signals can lead to the phospho- 
rylation of IKBo., which in turn leads to 
its ubiquination and degradation by the 
proteasome. in the alternative pathway, 
controlled degradation of the carboxy- 
terminal half of ~105 by the proteasome 
produces active p65/p50 dimer. Active 
NF-KB produced by either pathway 
then translocates into the nucleus and 
activates NF-&-responsive genes. 
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degraded, leaving the amino-terminal p50 intact. This is 
the first instance in which the proteasome performs regu- 
lated proteolytic processing instead of completely degrad- 
ing a protein; presumably other examples will be found. 
The mechanism for preventing the hydrolysis of the 
amino terminus of NF-KB is still unclear, however. 
NF-KB functions both as the initiator and as an amplifier 
of the inflammatory response. Not only does it promote 
the transcription of genes for inflammatory cytokines 
which can activate leukocytes, but it also directs the expres- 
sion of cell adhesion molecules which lead to the recruit- 
ment of leukocytes to inflammatory sites. Furthermore, 
NF-KB stimulates the synthesis of more ~105 and IKB~, 
and thus provides more substrate, generating a positive 
feedback loop. NF-KB is believed to be the main regulator 
initiating and sustaining the inflammatory state in both 
acute disease states (e.g. sepsis, ARDs, and acute transplant 
rejection) and chronic conditions (e.g. rheumatoid arthritis, 
inflammatory bowel disease, and asthma). 
Prospects for anti-inflammatory proteasome inhibitors 
Inhibitors of the 26s proteasome have been shown to sta- 
bilize IKBIX and to block the processing of p105 [39,40], 
and might therefore suppress inflammation by inhibiting 
expression of NF-KB-responsive genes. Both the tripep- 
tide aldehyde, MG 132 (Cbz-Leu-Leu-Leucinal), which 
reversibly binds to the active sites of the proteasome [30] 
and the natural product, lactacystin [23], which irre- 
versibly acylates the active site threonines, can penetrate 
living cells, block the activation of NF-KB, and thus 
prevent the expression of IL-2, TNF-a, ICAM-1, 
VCAM-1 and E-selectin (441. This ability of inhibitors of 
the 26s proteasome [39,40,44] to block activation of NF- 
KB has been demonstrated in multiple cell types.At con- 
centrations of the drug that half-maximally inhibit 
proteasome-dependent NF-KB activation (EDso), the 
expression of genes encoding cytokines and cell adhesion 
molecules is almost completely suppressed a. Chen,V.J. 
Palombella, S. Tagerud & S. Brand, unpublished data). The 
ability of proteasome inhibitors to block the inflamma- 
tory response has also recently been demonstrated in vim 
in animal models of human disease, including delayed- 
type hypersensitivity reactions and the gastropathy 
induced by non-steroidal anti-inflammatory drugs. But, as 
noted above, the proteasome has many other important 
functions, and blocking its activity may therefore have 
some untoward effects. It remains to be seen whether 
our exciting new knowledge about the ubiquitin-protea- 
some pathway can be translated into useful therapies for 
debilitating inflammatory diseases in humans. 
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